HAVCR2 and cancer: Anti-TIM-3 antibodies, mostly in combination with an anti-PD-1/PD-L1 blockade, are currently being investigated in clinical trials for the treatment of advanced cancers, and have shown encouraging early efficacy results with no serious adverse events or dose-limiting toxicities [21,30,47].